Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 994

Next Previous
Drug Profile

TAK 994

Alternative Names: TAK-994

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor type 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Narcolepsy

Most Recent Events

  • 26 Jul 2023 Interim adverse events and efficacy data from a phase-III trial in Narcolepsy released by Takeda
  • 28 Dec 2021 Takeda terminates phase II trial in Narcolepsy (PO) in China, Italy, Finland, Netherlands, Czech Republic, Hungary, Spain, South Korea, France and Canada due to emergence of safety signals (NCT04096560)
  • 03 Nov 2021 Takeda terminates phase II for Narcolepsy in US, Canada, Czech Republic, Finland, France, Hungary, Italy, Japan, South Korea and Spain (PO) in November 2021 (NCT04820842)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top